Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Koji Murota) as unlimited liability partner, has made an investment in ("KORAGEN PHARMA") (Head office: Nishikyo-ku, Kyoto; Representative Director: Hiroshi Nose), which conducts joint research with Kyoto University.

Execution of Investment in 0Collagen Pharma, Inc.
Collagen Pharma is a venture company that manufactures and sells research reagents using artificial collagen-like polypeptides and conducts research and development of medical devices.

Collagen Pharma has succeeded in chemically synthesizing an artificial collagen-like polypeptide with a triple-helical structure similar to collagen existing in vivo, which has been difficult to form until now, without using biologically derived materials. Furthermore, this artificial collagen-like polypeptide has high potential as a biomaterial for medical use because it can be given new bioactivity and its shape, physical properties, and biodegradability can be controlled.

Using this new material, Collagen Pharma will work with Kyoto Prefectural University of Medicine, Waseda University, and Kyoto University, with support from the Japan Agency for Medical Research and Development (AMED), to develop a medical device for macular hole, a disease that causes vision loss and distorted vision due to the vitreous body pulling on the retina and creating a hole in the center of the retina, The project is supported by the Japan Agency for Medical Research and Development (AMED) and is being conducted in collaboration with Kyoto Prefectural University of Medicine, Waseda University and Kyoto University. With Kyoto University, we will conduct joint research with Professor Tomiyoshi Yamashita of the Department of Clinical Pharmacology, Graduate School of Pharmaceutical Sciences on the pharmacokinetics and safety evaluation of the developed substance.

Kyoto iCAP has evaluated the high potential of the artificial collagen-like polypeptide developed by KORAGEN PHARMA and the possibility of developing a medical device for the indication of macular hole, which will be the first effort to utilize the artificial collagen-like polypeptide as a biomaterial for medical use. Ltd. and Nissui Pharmaceutical Co., Ltd. agreed to a third-party allocation of new shares totaling 47.25 million yen by Collagen Pharma, and invested 31.5 million yen.

Outline of KORAGEN PHARMA K.K.

Establishment	April 14, 2011
Business	Manufacture and sale of research reagents utilizing artificial collagen-like polypeptides and research and development of biomaterials for medical use
Head Office Location	1-39 Goryo-Ohara, Nishikyo-ku, Kyoto, 2104, Kyodai Katsura Venture Plaza South Bldg.
President & CEO	Hiroshi Nose